Orforglipron (Foundayo): The New Weight-Loss Pill

A new kind of weight-loss medication has arrived — and it comes as a once-daily pill rather than an injection. In April 2026, the U.S. Food and Drug Administration approved Foundayo (orforglipron), the first GLP-1 pill that can be taken any time of day with no food or water restrictions.

What has drawn the most attention, though, is how it stacked up against the competition. In a head-to-head trial, orforglipron outperformed oral semaglutide — the pill form of the same medicine sold as the well-known brands Ozempic and Wegovy — on both blood sugar and weight loss.

What Foundayo Is — and How It Works

Orforglipron belongs to the same drug class as semaglutide and tirzepatide: GLP-1 receptor agonists. These medicines mimic a natural gut hormone that helps regulate appetite and blood sugar, curbing hunger and slowing digestion so people tend to eat less.

The difference is in the design. Most GLP-1 drugs are injectables, and the existing oral option, semaglutide, must be taken on an empty stomach with strict water and timing rules. Orforglipron is a small-molecule pill that skips those restrictions — a practical edge for long-term use, since convenience often drives whether people stick with a treatment.

How It Compared With Oral Semaglutide

The head-to-head data came from a 52-week trial of 1,698 adults with type 2 diabetes whose blood sugar wasn’t well controlled on metformin. Participants took either orforglipron or oral semaglutide. Published in The Lancet, the results showed orforglipron came out ahead on the main measure — reduction in A1C, a marker of average blood sugar — and on weight.

In its broader development program, orforglipron produced average body-weight reductions of roughly 7.5% to 11% at 72 weeks in adults without diabetes, compared with about 2% on placebo. It also improved waist circumference, blood pressure, and cholesterol markers.

Important Safety Information

The most common side effects are gastrointestinal — nausea, constipation, diarrhea, vomiting, indigestion, and abdominal pain — along with headache and hair loss. These tend to appear as the dose is increased. Combining Foundayo with another GLP-1 medicine is not recommended, and it hasn’t been shown to be safe or effective in children.

Cost and Availability

Foundayo is available by prescription through a reduced-calorie diet and increased physical activity. Eligible patients with commercial insurance may pay as little as $25 a month with a savings card, while self-pay pricing starts around $149 a month for the lowest dose. Eligible Medicare Part D patients may access it for about $50 a month.

What It’s Approved For — and What’s Still Being Studied

An important distinction: Foundayo is currently approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition — not yet for type 2 diabetes. The diabetes data, though promising, comes from trials still working through the regulatory process, and the manufacturer is pursuing that indication separately.

Researchers are also studying orforglipron for a range of related conditions, including obstructive sleep apnea, cardiovascular disease risk factors, and osteoarthritis knee pain.

What It Means for Patients

For people who have hesitated over injections or struggled with the strict rules around oral semaglutide, a flexible daily pill is a meaningful new option. But it isn’t a shortcut: GLP-1 medicines work best alongside diet and activity changes, carry real side effects, and require medical supervision. Anyone weighing Foundayo should talk with a healthcare provider about whether it fits their health history and goals.